Search

Your search keyword '"KANTOLA, ILKKA"' showing total 413 results

Search Constraints

Start Over You searched for: Author "KANTOLA, ILKKA" Remove constraint Author: "KANTOLA, ILKKA"
413 results on '"KANTOLA, ILKKA"'

Search Results

1. Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study.

2. Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial

5. BLOOD PRESSURE CONTROL WITH APROCITENTAN IN RESISTANT HYPERTENSION

6. EFFECT OF HIGH DOSE APROCITENTAN IN PATIENTS WITH RESISTANT HYPERTENSION NOT CONTROLLED BY LOW DOSE

8. Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial

9. Outcomes with Finerenone in Participants with Stage 4 CKD and Type 2 Diabetes: A FIDELITY Subgroup Analysis

11. Aging Fabry disease patients

12. Hemodynamic Bedside Monitoring Instrument with Pressure and Optical Sensors: Validation and Modality Comparison.

13. Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study

14. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial

15. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial

21. Start age of enzyme replacement therapy (ERT) did not effect ECG parameters in Fabry disease patients (FD) treated by ERT for 5 years

22. Clinical outcomes among young patients with Fabry disease who initiated agalsidase beta treatment before 30 years of age: An analysis from the Fabry Registry

23. P005: Head-to-head trial of pegunigalsidase alfa vs agalsidase beta in Fabry disease: Phase 3 randomized, double-blind, BALANCE Study 2-year results

25. Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial

26. An expert consensus on the recommendations for the use of biomarkers in Fabry disease

30. Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial

32. Pascal’s Wager and Moral Tutiorism

35. Cardiomyopathy associated with the Ala143Thr variant of the α-galactosidase A gene

37. Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study

42. Identifying and treating resistant hypertension in PRECISION: A randomized long‐term clinical trial with aprocitentan.

44. Self-monitoring of blood pressure in hypertension: A systematic review and individual patient data meta-analysis

Catalog

Books, media, physical & digital resources